With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
|Articles|June 17, 2016
HIV Patient Experience Highlights Specialty Pharmacy Week in Review
Author(s)Davy James, Managing Editor
Top articles of the week on Specialty Pharmacy Times.
Advertisement
[<a href="//storify.com/pharmacytimes/hiv-patient-experience-highlight-specialty-pharmac" target="_blank">View the story "HIV Patient Experience Highlight Specialty Pharmacy Week in Review" on Storify</a>]
Advertisement
Related to this article
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Once-daily oral deucrictibant extended-release significantly reduced hereditary angioedema attacks compared with placebo in the pivotal phase 3 CHAPTER-3 trial.
The FDA has approved rebisufligene etisparvovec-hopf (Fayuvi), the first treatment designed to alter the course of mucopolysaccharidosis type IIIA.
This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Adult Pneumococcal Immunizations: A Practical Guide for Pharmacists
2
How Pharmacists Overcome PCSK9 Inhibitor Access Barriers
3
From Reactive to Proactive: AI's Role in Modern Pharmacy Safety
4
Trial Ended Early When Venetoclax Plus DA-EPOCH-R Did Not Improve Outcomes in Double-Hit Lymphoma
5